Comprehensive Review on Antimicrobial Resistance: Mechanisms, Drivers, Impacts, and Strategies for Mitigation

Aniket Jotiram Sawant, Samarth Rajendra Thete, Krushna Vinodrao Kadam
Swami Institute of Pharmacy, Abhona Nashik

***Abstract*—Antimicrobial resistance (AMR) is a pressing global health crisis, undermining the efficacy of antibiotics and increasing morbidity, mortality, and economic burdens. This review synthesizes current literature on AMR, detailing its molecular mechanisms, drivers, global impacts, and mitigation strategies. Bacterial AMR is projected to cause 39 million deaths by 2050, driven by antibiotic overuse in healthcare and agriculture, inadequate infection control, and a dwindling antibiotic pipeline. Resistance mechanisms, including enzymatic inactivation, target modification, efflux pumps, reduced permeability, biofilms, and metabolic bypass, enable rapid microbial adaptation. Strategies such as antibiotic stewardship, enhanced surveillance, infection prevention, and innovative technologies offer hope, but global coordination is critical. The One Health approach, integrating human, animal, and environmental health, is essential to address AMR's complexity. This review calls for urgent, multisectoral action to preserve antimicrobial efficacy and mitigate the escalating threat to global health.**

***Keywords*— Antimicrobial resistance, antibiotic stewardship, resistance mechanisms, One Health, global health**

I. INTRODUCTION

Antimicrobial resistance (AMR) occurs when microorganisms, including bacteria, viruses, fungi, and parasites, develop the ability to withstand antimicrobial treatments, rendering drugs like antibiotics, antivirals, and antifungals ineffective (1). This phenomenon threatens modern medicine by complicating the treatment of infections, increasing disease transmission, and elevating risks of severe illness and death. The World Health Organization (WHO) ranks AMR among the top ten global health threats, emphasizing its impact on healthcare systems, economies, and societal well-being (1). A landmark 2024 study in *The Lancet* projects that bacterial AMR will cause 39 million deaths between 2025 and 2050, with low- and middle-income countries (LMICs) bearing the heaviest burden (2). The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, such as carbapenem-resistant *Enterobacteriaceae* (CRE) and methicillin-resistant *Staphylococcus aureus* (MRSA), underscores the urgency of addressing this crisis.

AMR's complexity stems from its biological, behavioral, and systemic drivers. Debates persist over the relative contributions of clinical antibiotic misuse versus agricultural overuse, with both sectors significantly influencing resistance patterns (3). For example, inappropriate prescribing in outpatient settings and the use of antibiotics as growth promoters in livestock have accelerated the spread of resistance genes like *bla*NDM-1 and *tet* (4). Additionally, global travel and trade facilitate the rapid dissemination of resistant strains, as seen with the New Delhi metallo-β-lactamase (NDM-1) gene, first identified in India in 2008 and now detected worldwide (5). This review aims to provide a comprehensive analysis of AMR's mechanisms, drivers, impacts, and mitigation strategies, synthesizing recent literature to inform policy, research, and public health initiatives. By addressing knowledge gaps, particularly in LMICs, and advocating for a One Health approach, this review seeks to contribute to global efforts to combat AMR.

II. HISTORICAL CONTEXT

The antibiotic era began with Alexander Fleming's serendipitous discovery of penicillin in 1928, marking a transformative period in medical history (6). This "golden age" of antibiotic discovery, spanning the 1930s to 1950s, introduced major classes such as sulfonamides (1932), aminoglycosides (1943), tetracyclines (1948), and glycopeptides (1955), extending human lifespan by an estimated 23 years and saving millions of lives (6). However, resistance emerged almost immediately

after clinical use, driven by microbial evolutionary pressures. For example, penicillin-resistant *S. aureus* was reported by 1945, just four years after penicillin's introduction, and tetracycline resistance was documented within five years of its 1948 debut (7).

Table 1. Timeline of Antibiotic Discovery and Resistance

Antibiotic Class	Discovery	Clinical Use	Resistance Reported
Organoarsenics	1909	1910	1912
Penicillins	1928	1941	1945
Sulfonamides	1932	1935	1939
Aminoglycosides	1943	1946	1946
Tetracyclines	1948	1948	1953
Glycopeptides	1955	1958	1987

The rapid emergence of resistance reflects an evolutionary arms race between microbes and antimicrobial agents. Early antibiotics targeted a limited range of bacterial processes, allowing bacteria to adapt through mutations or horizontal gene transfer via plasmids, transposons, and integrons (7). By the 1980s, antibiotic discovery slowed significantly due to scientific and economic challenges, with no new major classes introduced since the lipopeptides (e.g., daptomycin) in the early 2000s (8). This stagnation, coupled with the global spread of resistance genes, has fueled the current AMR crisis. For instance, the *mecA* gene, conferring methicillin resistance in MRSA, has spread across healthcare and community settings, complicating treatment of skin, bloodstream, and respiratory infections (9).

Debates continue over the primary drivers of resistance. Clinical misuse, such as overprescribing broad-spectrum antibiotics, has been implicated in the rise of resistant pathogens like *Clostridium difficile* (10). Simultaneously, agricultural use of antibiotics, particularly in livestock, has contributed to environmental reservoirs of resistance genes, as seen with tetracycline resistance in soil and water near farms (11). Understanding this historical context is critical for designing effective interventions to address AMR's root causes and prevent further escalation.

III. MECHANISMS OF RESISTANCE

Microorganisms employ diverse strategies to evade antimicrobials, often mediated by chromosomal mutations or acquired resistance genes transferred via plasmids, transposons, or integrons (12). These mechanisms, detailed below, enable rapid adaptation and contribute to the rise of MDR and XDR pathogens.

3.1 Enzymatic Inactivation

Enzymatic inactivation involves the production of enzymes that chemically modify or degrade antibiotics. The most prominent example is β-lactamases, which hydrolyze the β-lactam ring in penicillins, cephalosporins, and carbapenems, disrupting their ability to inhibit cell wall synthesis (12). Over 1,000 β-lactamases have been identified, ranging from narrow-spectrum enzymes to extended-spectrum β-lactamases (ESBLs) like CTX-M, prevalent in *Escherichia coli* and *Klebsiella pneumoniae*, and carbapenemases like NDM-1 and KPC (13). NDM-1, first identified in 2008, has spread globally, conferring resistance to last-resort carbapenems and complicating treatment of Gram-negative infections (14). Other enzymes, such as aminoglycoside-modifying enzymes (e.g., acetyltransferases) and chloramphenicol acetyltransferases, inactivate aminoglycosides and chloramphenicol, respectively, by adding chemical groups that block antibiotic function (12).

3.2 Target Modification

Bacteria alter antibiotic target sites to reduce or eliminate drug binding. In MRSA, the *mecA* gene encodes an alternative penicillin-binding protein (PBP2a) with low affinity for β-lactam antibiotics, allowing cell wall synthesis to continue (12). Similarly, rifampicin resistance in *Mycobacterium tuberculosis* results from mutations in the *rpoB* gene, which encodes the RNA polymerase β-subunit, altering the rifampicin-binding site (15). Tetracycline resistance often involves ribosomal protection proteins like Tet(M), which prevent tetracycline from binding to bacterial ribosomes, ensuring uninterrupted protein synthesis (12).

3.3 Efflux Pumps

Efflux pumps are membrane-bound proteins that actively expel antibiotics, reducing intracellular drug concentrations below therapeutic levels. The AcrAB-TolC system in *E. coli* is a well-characterized tripartite pump that extrudes tetracyclines, fluoroquinolones, and β-lactams, contributing to multidrug resistance (12). Overexpression of efflux pumps, often triggered by environmental stress or mutations, exacerbates resistance, as seen in *Pseudomonas aeruginosa* infections in cystic fibrosis patients (16).

3.4 Reduced Permeability

Gram-negative bacteria limit antibiotic entry by altering outer membrane porins. For example, *P. aeruginosa* reduces carbapenem uptake through mutations in the OprD porin, while *Enterobacteriaceae* downregulate porins to block cephalosporin entry (12). This mechanism often synergizes with efflux pumps and β-lactamases, creating robust resistance profiles.

3.5 Biofilm Formation

Biofilms are structured bacterial communities encased in a protective extracellular matrix, hindering antibiotic penetration and shielding dormant cells from immune responses (12). Biofilms are implicated in chronic infections, such as *P. aeruginosa* in cystic fibrosis or *S. epidermidis* on indwelling medical devices like catheters (17). The matrix physically blocks antibiotics, while slow-growing cells are less susceptible to drugs targeting active division, such as β-lactams.

3.6 Alternative Metabolic Pathways

Bacteria bypass antibiotic-targeted pathways by adopting alternative routes. Vancomycin-resistant enterococci (VRE) modify cell wall precursors, replacing D-alanine-D-alanine with D-alanine-D-lactate, reducing vancomycin's binding affinity (12). Similarly, some bacteria develop alternative folate synthesis pathways to evade sulfonamides and trimethoprim (18).

Table 2. Key Resistance Mechanisms

Mechanism	Description	Examples
Enzymatic Inactivation	Enzyme-mediated antibiotic degradation	CTX-M, NDM-1 in *Enterobacteriaceae*
Target Modification	Altered antibiotic binding sites	MRSA (*mecA*), rifampicin resistance
Efflux Pumps	Active antibiotic extrusion	AcrAB-TolC in *E. coli*
Reduced Permeability	Limited antibiotic entry via porins	OprD mutations in *P. aeruginosa*

3.7 Genetic Basis and Global Spread

Resistance mechanisms are often plasmid-mediated, enabling rapid dissemination across bacterial species. For instance, NDM-1 is frequently encoded on plasmids, facilitating its spread from India to over 70 countries within a decade (14). Horizontal gene transfer via conjugative plasmids, integrons, and bacteriophages accelerates the global dissemination of resistance, underscoring the need for robust surveillance systems (19).

IV. DRIVERS OF AMR

AMR is driven by a complex interplay of biological, behavioral, economic, and systemic factors, each contributing to the emergence and spread of resistant pathogens.

4.1 Overuse and Misuse in Healthcare

Antibiotic overuse in human healthcare is a primary driver of AMR. Studies estimate that 30–50% of antibiotic prescriptions for respiratory infections, such as bronchitis or the common cold, are unnecessary, as these conditions are predominantly viral (20). In the United States, the Centers for Disease Control and Prevention (CDC) reports that 90% of such prescriptions are issued by general practitioners, often due to patient pressure, diagnostic uncertainty, or time constraints (21). Broad-spectrum antibiotics, such as fluoroquinolones, are frequently overprescribed, contributing to the rise of MDR pathogens like *C. difficile* and MRSA (22). In LMICs, over-the-counter antibiotic access, self-medication, and limited diagnostic tools exacerbate misuse, with studies in Southeast Asia showing up to 80% of antibiotic use occurring without prescriptions (23).

4.2 Agricultural Antibiotic Use

The use of antibiotics in agriculture, particularly as growth promoters in livestock, significantly contributes to AMR. In the United States, approximately 70% of antibiotics are used in agriculture, with much allocated to non-therapeutic purposes (24). Antibiotics like tetracyclines and macrolides, used in animal feed, leave residues in meat, milk, and eggs, leading to chronic human exposure and fostering resistance in the microbiome (25). Environmental contamination from livestock waste spreads resistance genes, such as *tet* genes, into soil, water, and crops, as documented in studies near poultry farms in China (26). Resistant bacteria, including *Salmonella* and *E. coli*, are transmitted via the food chain, with outbreaks linked to contaminated poultry and pork (27). While the European Union banned antibiotic growth promoters in 2006, many LMICs continue the practice due to economic incentives and weak regulations (28).

4.3 Poor Infection Control

Inadequate infection prevention and control (IPC) measures facilitate the spread of resistant bacteria. Hospitals are hotspots for resistant infections due to high antibiotic use, invasive procedures, and vulnerable patient populations (29). Poor hygiene practices, such as inadequate handwashing or improper sterilization, enable transmission of pathogens like MRSA, CRE, and *Acinetobacter baumannii*. The WHO estimates that healthcare-associated infections (HAIs) affect 7–10% of hospitalized patients globally, with rates exceeding 20% in LMICs due to underfunded IPC programs (30). In communities, poor sanitation, lack of clean water, and overcrowding amplify resistance, particularly for diseases like multidrug-resistant tuberculosis (MDR-TB) (31).

4.4 Lack of New Antibiotics

The antibiotic development pipeline is critically limited, with only 97 antibacterial agents in clinical development by 2023, including just 12 in Phase 3 trials (32). Scientific challenges, such as the difficulty of targeting Gram-negative bacteria with complex cell walls, and economic disincentives, including short market life due to resistance, deter investment (33). Pharmaceutical companies have largely abandoned antibiotic research, with major firms like Pfizer and Novartis exiting the field (34). Innovative funding models, such as the UK's subscription-based "Netflix" model and public-private partnerships like CARB-X, aim to stimulate development, but progress remains slow (35).

4.5 Economic and Systemic Challenges

Economic barriers, including low profitability of antibiotics and high development costs, exacerbate AMR. Antibiotics are typically used for short courses, unlike drugs for chronic conditions, limiting revenue potential (36). In LMICs, reliance on affordable, older antibiotics due to cost constraints perpetuates resistance, while limited access to diagnostics hinders appropriate prescribing (37). Regulatory hurdles, such as lengthy approval processes, further discourage innovation. Global coordination is lacking, with fragmented implementation of the WHO's Global Action Plan on AMR (2015), particularly in resource-constrained regions (38).

V. IMPACTS OF AMR

AMR exacts a profound toll on global health and economies. In 2021, bacterial AMR directly caused 1.14 million deaths and was associated with 4.71 million deaths, according to a 2024 *Lancet* study (2). By 2050, these figures are projected to rise to 1.91 million direct and 8.22 million associated deaths, with LMICs facing the greatest burden due to limited healthcare infrastructure (2). Economically, AMR costs an estimated $66 billion annually for treatment and lost productivity, with projections of $159 billion by 2050 (39). In the European Union, AMR results in 2.5 million extra hospital days and €1.5 billion in annual losses, impacting healthcare systems and workforce productivity (40).

AMR also undermines medical advancements, threatening procedures like organ transplants, chemotherapy, and surgeries, which rely on effective antibiotics to prevent infections (41). The rise of MDR and XDR pathogens, such as CRE and MDR *P. aeruginosa*, limits treatment options, increasing reliance on toxic or less effective drugs like colistin (42). Socially, AMR disproportionately affects vulnerable populations, including children, the elderly, and those in LMICs, exacerbating health inequities (43).

VI. CURRENT STATUS

The 2022 WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) report reveals alarming resistance trends: 42% median resistance

for third-generation cephalosporin-resistant *E. coli* across 76 countries, 35% for MRSA, and over 50% for *K. pneumoniae* and *Acinetobacter* spp. in bloodstream infections (44). Regional variations are stark, with South Asia reporting higher resistance rates due to widespread antibiotic misuse and poor surveillance (45). Data gaps in LMICs, where diagnostic and reporting systems are limited, hinder accurate assessments, underscoring the need for expanded surveillance networks (46).

Table 3. Global Resistance Rates (2022, GLASS)

Pathogen	Resistance Rate (Median)	Notes
Third-gen Cephalosporin-resistant *E. coli*	42%	76 countries
MRSA	35%	Global
Klebsiella pneumoniae	>50%	Bloodstream infections
Acinetobacter spp.	>50%	Bloodstream infections

VII. STRATEGIES TO COMBAT AMR

Combating AMR requires a multifaceted approach, integrating clinical, agricultural, and environmental interventions.

7.1 Antibiotic Stewardship

Antibiotic stewardship programs promote judicious prescribing, reducing unnecessary use. In US hospitals, such programs have decreased antibiotic consumption by 22%, improving patient outcomes and reducing resistance rates (47). Decision-support tools, clinician education, and antimicrobial guidelines are critical components, particularly in primary care settings where overprescribing is prevalent (48).

7.2 Infection Prevention

Robust IPC measures, including hand hygiene, vaccination, and sterilization, reduce resistant strain transmission. Vaccination against pathogens like *Streptococcus pneumoniae* has decreased antibiotic use by preventing infections (49). In hospitals, enhanced sanitation and isolation protocols have lowered HAI rates, as demonstrated in Scandinavian countries with stringent IPC standards (50).

7.3 Surveillance

Global surveillance systems like GLASS and the US National Antimicrobial Resistance Monitoring System (NARMS) track resistance trends, informing policy and treatment guidelines (44). Expanding surveillance in LMICs, where data is sparse, is essential for understanding regional resistance patterns and guiding interventions (51).

7.4 Research and Development

Investment in novel antibiotics, diagnostics, and alternative therapies is critical. As of 2023, 97 antibacterials were in development, but only a fraction target priority pathogens like CRE (32). Alternatives, such as bacteriophage therapy, monoclonal antibodies, and microbiome-based treatments, show promise but require further validation (52). Rapid diagnostic tools, like point-of-care PCR, can guide precise prescribing, reducing misuse (53).

7.5 Public Education

Public awareness campaigns, such as the CDC's "Get Smart" initiative, educate communities about appropriate antibiotic use, reducing patient-driven demand (47). In LMICs, community-based programs addressing cultural perceptions of antibiotics as "quick fixes" have shown success in reducing self-medication (54).

7.6 Policy Initiatives

Regulatory reforms, such as banning non-therapeutic antibiotic use in agriculture, are effective, as seen in the EU's 2006 ban (55). The UK's 2024–2029 AMR action plan, targeting a 5% reduction in human antibiotic use, provides a model for national strategies, emphasizing stewardship, surveillance, and R&D investment (56).

VIII. FUTURE DIRECTIONS

Emerging technologies offer innovative solutions to combat AMR. Diagnostic biosensors enable rapid pathogen identification and resistance profiling, reducing inappropriate prescribing (57). Engineered antimicrobial surfaces, such as copper-coated hospital equipment, prevent bacterial colonization, while smart biomaterials like antibiotic-loaded nanoparticles target infections with precision (58). Cell engineering, including CRISPR-based approaches to disable resistance genes, and artificial intelligence for predicting resistance patterns are promising but require clinical validation (59).

The One Health approach, integrating human, animal, and environmental health, is critical for addressing AMR's interconnected drivers. Global policies must prioritize phasing out agricultural antibiotic use for growth promotion, as demonstrated by successes in Denmark and the Netherlands (60). Incentivizing R&D through market entry rewards and public-private partnerships can address the antibiotic pipeline's stagnation (61). Strengthening surveillance and research capacity in LMICs is essential to close data gaps and tailor interventions to regional needs (62).

IX. CONCLUSION

Antimicrobial resistance is a multifaceted global health crisis threatening medical progress and economic stability. Its molecular mechanisms—enzymatic inactivation, target modification, efflux pumps, and others—enable rapid microbial adaptation, while drivers like antibiotic overuse, poor infection control, and a limited drug pipeline exacerbate the problem. With projections of 39 million deaths by 2050, AMR demands urgent, coordinated action (2). Strategies such as antibiotic stewardship, infection prevention, surveillance, and innovative R&D offer hope, but their success hinges on global collaboration. The One Health framework, addressing human, animal, and environmental factors, is paramount. By bridging policy, research, and public health gaps, particularly in LMICs, we can preserve antimicrobial efficacy and safeguard future generations.

REFERENCES

[1] World Health Organization. Antimicrobial resistance fact sheet [Internet]. Geneva: WHO; 2023 [cited 2025 May 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

[2] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10458):1199-226.

[3] Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277-83.

[4] Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176-87.

[5] Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597-602.

[6] Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72-80.

[7] Aminov RI. Derivation of a precise and consistent timeline for antibiotic development. Front Microbiol. 2022;13:888088.

[8] Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013;66(10):571-91.

[9] Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629-41.

[10] Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-34.

[11] Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules. 2018;23(4):795.

[12] Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2):10.1128/microbiolspec.VMBF-0016-2015.

[13] Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247.

[14] Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11(5):355-62.

[15] Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-50.

[16] Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56(1):20-51.

[17] Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-22.

[18] Sköld O. Resistance to trimethoprim and sulfonamides. Vet Res. 2001;32(3-4):261-73.
[19] Stokes HW, Gillings MR. Gene flow, mobile genetic elements and the recruitment of antibiotic resistance genes into Gram-negative pathogens. FEMS Microbiol Rev. 2011;35(5):790-819.
[20] Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014;5(6):229-41.
[21] Centers for Disease Control and Prevention. Antibiotic prescribing and use in the U.S. [Internet]. Atlanta: CDC; 2023 [cited 2025 May 16]. Available from: https://www.cdc.gov/antibiotic-use/data/index.html
[22] Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155-64.
[23] Morgan DJ, Okeke IN, Laxminarayan R, et al. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011;11(9):692-701.
[24] Van Boeckel TP, Glennon EE, Chen D, et al. Reducing antimicrobial use in food animals. Science. 2017;357(6358):1350-2.
[25] Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24(4):718-33.
[26] Zhu YG, Johnson TA, Su JQ, et al. Diverse and abundant antibiotic resistance genes in Chinese swine farms. Proc Natl Acad Sci U S A. 2013;110(9):3435-40.
[27] Angulo FJ, Nargund VN, Chiller TC. Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J Vet Med B Infect Dis Vet Public Health. 2004;51(8-9):374-9.
[28] European Commission. Ban on antibiotics as growth promoters in animal feed enters into effect [Internet]. Brussels: EC; 2005 [cited 2025 May 16]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/IP_05_1687
[29] World Health Organization. Global report on infection prevention and control [Internet]. Geneva: WHO; 2022 [cited 2025 May 16]. Available from: https://www.who.int/publications/i/item/9789240051164
[30] Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228-41.
[31] World Health Organization. Global tuberculosis report 2023 [Internet]. Geneva: WHO; 2023 [cited 2025 May 16]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
[32] World Health Organization. Antibacterial agents in clinical and preclinical development: an overview and analysis [Internet]. Geneva: WHO; 2023 [cited 2025 May 16]. Available from: https://www.who.int/publications/i/item/9789240070158
[33] Årdal C, Balasegaram M, Laxminarayan R, et al. Antibiotic development: the 10 × '20 initiative and beyond. Lancet. 2020;395(10222):e49-50.
[34] Plackett B. Why big pharma has abandoned antibiotics. Nature. 2020;586(7829):S50-2.
[35] Outterson K, Rex JH. Global antibiotic R&D partnership models: lessons from the CARB-X experience. Clin Infect Dis. 2020;71(Suppl 3):S231-6.
[36] O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance [Internet]. 2016 [cited 2025 May 16]. Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
[37] Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 2005;5(8):481-93.
[38] World Health Organization. Global action plan on antimicrobial resistance [Internet]. Geneva: WHO; 2015 [cited 2025 May 16]. Available from: https://www.who.int/publications/i/item/9789241509763
[39] Center for Global Development. Economic impacts of antimicrobial resistance [Internet]. Washington, DC: CGD; 2023 [cited 2025 May 16]. Available from:

https://www.cgdev.org/publication/economic-impacts-antimicrobial-resistance

[40] European Centre for Disease Prevention and Control. Antimicrobial resistance has a huge economic impact too [Internet]. Stockholm: ECDC; 2022 [cited 2025 May 16]. Available from: https://www.ecdc.europa.eu/en/news-events/antimicrobial-resistance-huge-economic-impact-too

[41] World Health Organization. Antimicrobial resistance: a threat to global health security [Internet]. Geneva: WHO; 2019 [cited 2025 May 16]. Available from: https://www.who.int/news-room/feature-stories/detail/antimicrobial-resistance-a-threat-to-global-health-security

[42] Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8.

[43] Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057-98.

[44] World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) report: 2022 [Internet]. Geneva: WHO; 2022 [cited 2025 May 16]. Available from: https://www.who.int/publications/i/item/9789240062702

[45] Gandra S, Alvarez-Uria G, Turner P, et al. Antimicrobial resistance surveillance in low- and middle-income countries: progress and challenges in eight South Asian and Southeast Asian countries. Clin Microbiol Rev. 2020;33(3):e00048-19.

[46] Iskandar K, Sartelli M, Tabbal M, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. Antimicrob Resist Infect Control. 2021;10(1):63.

[47] Centers for Disease Control and Prevention. Antimicrobial resistance threats [Internet]. Atlanta: CDC; 2023 [cited 2025 May 16]. Available from: https://www.cdc.gov/antimicrobial-resistance/data-research/threats.html

[48] Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-77.

[49] Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary pneumococcal vaccines. Vaccine. 2018;36(52):7945-50.

[50] Harbarth S, Sax H, Gastmeier P. The preventable proportion of healthcare-associated infections 2005–2016: systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018;39(11):1277-95.

[51] Ashley EA, Recht J, Chua A, et al. Antimicrobial resistance surveillance in low- and middle-income countries: current approaches and future perspectives. Clin Infect Dis. 2020;71(Suppl 2):S133-40.

[52] Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25(2):219-32.

[53] Timbrook TT, Morton JB, McConeghy KW, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64(1):15-23.

[54] Haenssgen MJ, Xayavong T, Charoenboon N, et al. The consequences of AMR education and awareness raising: outputs, outcomes, and behavioural impacts of an antibiotic-related educational activity in Lao PDR. Antibiotics (Basel). 2018;7(4):95.

[55] European Medicines Agency. Sales of veterinary antimicrobial agents in 31 European countries in 2022 [Internet]. Amsterdam: EMA; 2023 [cited 2025 May 16]. Available from: https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2022_en.pdf

[56] UK Government. Confronting antimicrobial resistance 2024 to 2029 [Internet]. London: UK Government; 2024 [cited 2025 May 16]. Available from: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029

[57] Syal K, Mo M, Yu H, et al. Current and emerging techniques for antibiotic susceptibility testing. Trends Biotechnol. 2017;35(6):522-33.

[58] Makabenta JMV, Nabawy A, Li CH, et al. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol. 2021;19(1):23-36.
[59] Strich JR, Chertow DS. CRISPR-Cas biology and its application to infectious diseases. J Infect Dis. 2021;223(12 Suppl 2):S16-22.
[60] Aarestrup FM. The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risk, effects of interventions and the way forward. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140085.
[61] Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016;16(4):500-5.
[62] Sriram A, Kalanxhi E, Kapoor G, et al. State of the world's antibiotics 2021: a global analysis of antimicrobial resistance and its drivers [Internet]. Washington, DC: Center for Disease Dynamics, Economics & Policy; 2021 [cited 2025 May 16]. Available from: https://cddep.org/publications/state-worlds-antibiotics-2021/